Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

RAPid signaling in platelets.

Nieman MT.

Blood. 2018 Nov 1;132(18):1864-1865. doi: 10.1182/blood-2018-09-872093. No abstract available.

PMID:
30385489
2.

Assessment of whole blood coagulation with a microfluidic dielectric sensor.

Maji D, De La Fuente M, Kucukal E, Sekhon UDS, Schmaier AH, Sen Gupta A, Gurkan UA, Nieman MT, Stavrou EX, Mohseni P, Suster MA.

J Thromb Haemost. 2018 Oct;16(10):2050-2056. doi: 10.1111/jth.14244. Epub 2018 Sep 25.

3.

Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?

Han X, Nieman MT.

Ann Transl Med. 2018 Feb;6(3):56. doi: 10.21037/atm.2017.11.36. No abstract available.

4.

Cryo-EM structure of 5-HT3A receptor in its resting conformation.

Basak S, Gicheru Y, Samanta A, Molugu SK, Huang W, Fuente M, Hughes T, Taylor DJ, Nieman MT, Moiseenkova-Bell V, Chakrapani S.

Nat Commun. 2018 Feb 6;9(1):514. doi: 10.1038/s41467-018-02997-4.

5.

Factor XII and uPAR upregulate neutrophil functions to influence wound healing.

Stavrou EX, Fang C, Bane KL, Long AT, Naudin C, Kucukal E, Gandhi A, Brett-Morris A, Mumaw MM, Izadmehr S, Merkulova A, Reynolds CC, Alhalabi O, Nayak L, Yu WM, Qu CK, Meyerson HJ, Dubyak GR, Gurkan UA, Nieman MT, Sen Gupta A, Renné T, Schmaier AH.

J Clin Invest. 2018 Mar 1;128(3):944-959. doi: 10.1172/JCI92880. Epub 2018 Jan 29.

6.

PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.

Han X, Nieman MT.

Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):287-289. doi: 10.1161/ATVBAHA.117.310550. No abstract available.

7.

Optimizing the presentation of bleeding and thrombosis data: Responding to censored data using Kaplan-Meier curves.

Bouck EG, Zunica ER, Nieman MT.

Thromb Res. 2017 Oct;158:154-156. doi: 10.1016/j.thromres.2017.09.011. Epub 2017 Sep 12. No abstract available.

8.

Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth.

Michael JV, Wurtzel JGT, Mao GF, Rao AK, Kolpakov MA, Sabri A, Hoffman NE, Rajan S, Tomar D, Madesh M, Nieman MT, Yu J, Edelstein LC, Rowley JW, Weyrich AS, Goldfinger LE.

Blood. 2017 Aug 3;130(5):567-580. doi: 10.1182/blood-2016-11-751099. Epub 2017 May 12.

9.

Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.

Sharma R, Waller AP, Agrawal S, Wolfgang KJ, Luu H, Shahzad K, Isermann B, Smoyer WE, Nieman MT, Kerlin BA.

J Am Soc Nephrol. 2017 Sep;28(9):2618-2630. doi: 10.1681/ASN.2016070789. Epub 2017 Apr 19.

10.

Protease-activated Receptor-4 Signaling and Trafficking Is Regulated by the Clathrin Adaptor Protein Complex-2 Independent of β-Arrestins.

Smith TH, Coronel LJ, Li JG, Dores MR, Nieman MT, Trejo J.

J Biol Chem. 2016 Aug 26;291(35):18453-64. doi: 10.1074/jbc.M116.729285. Epub 2016 Jul 11.

11.

Protease-activated receptors in hemostasis.

Nieman MT.

Blood. 2016 Jul 14;128(2):169-77. doi: 10.1182/blood-2015-11-636472. Epub 2016 Apr 28. Review.

12.

Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets.

Rowley JW, Chappaz S, Corduan A, Chong MM, Campbell R, Khoury A, Manne BK, Wurtzel JG, Michael JV, Goldfinger LE, Mumaw MM, Nieman MT, Kile BT, Provost P, Weyrich AS.

Blood. 2016 Apr 7;127(14):1743-51. doi: 10.1182/blood-2015-07-661371. Epub 2016 Jan 14.

13.

Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4).

Mumaw MM, de la Fuente M, Arachiche A, Wahl JK 3rd, Nieman MT.

Thromb Res. 2015 Jun;135(6):1165-71. doi: 10.1016/j.thromres.2015.03.027. Epub 2015 Apr 9.

14.

Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.

Kerlin BA, Waller AP, Sharma R, Chanley MA, Nieman MT, Smoyer WE.

J Am Soc Nephrol. 2015 Dec;26(12):3009-19. doi: 10.1681/ASN.2014111097. Epub 2015 Apr 8.

15.

PARtitioning protease signaling.

Nieman MT.

Blood. 2015 Mar 19;125(12):1853-5. doi: 10.1182/blood-2015-01-623835.

PMID:
25792732
16.

Race differences in platelet reactivity: is protease activated receptor 4 a predictor of response to therapy?

Mumaw MM, Nieman MT.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2524-6. doi: 10.1161/ATVBAHA.114.304727. No abstract available.

17.

Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis.

Mumaw MM, de la Fuente M, Noble DN, Nieman MT.

J Thromb Haemost. 2014 Aug;12(8):1331-41. doi: 10.1111/jth.12619. Epub 2014 Jun 27.

18.

Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets.

Arachiche A, de la Fuente M, Nieman MT.

PLoS One. 2014 May 15;9(5):e97724. doi: 10.1371/journal.pone.0097724. eCollection 2014.

19.

Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin.

Arachiche A, Mumaw MM, de la Fuente M, Nieman MT.

J Biol Chem. 2013 Nov 8;288(45):32553-62. doi: 10.1074/jbc.M113.472373. Epub 2013 Oct 4.

20.

Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets.

Arachiche A, de la Fuente M, Nieman MT.

PLoS One. 2013;8(2):e55740. doi: 10.1371/journal.pone.0055740. Epub 2013 Feb 6. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/0956857d-ecf5-4fb7-a834-131915a38a6a.

21.

Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.

Fang C, Stavrou E, Schmaier AA, Grobe N, Morris M, Chen A, Nieman MT, Adams GN, LaRusch G, Zhou Y, Bilodeau ML, Mahdi F, Warnock M, Schmaier AH.

Blood. 2013 Apr 11;121(15):3023-32. doi: 10.1182/blood-2012-09-459156. Epub 2013 Feb 5. Erratum in: Blood. 2014 Mar 6;123(10):1622.

22.

Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4.

de la Fuente M, Noble DN, Verma S, Nieman MT.

J Biol Chem. 2012 Mar 23;287(13):10414-23. doi: 10.1074/jbc.M112.341438. Epub 2012 Feb 8.

23.

Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis.

Adams GN, LaRusch GA, Stavrou E, Zhou Y, Nieman MT, Jacobs GH, Cui Y, Lu Y, Jain MK, Mahdi F, Shariat-Madar Z, Okada Y, D'Alecy LG, Schmaier AH.

Blood. 2011 Apr 7;117(14):3929-37. doi: 10.1182/blood-2010-11-318527. Epub 2011 Feb 4.

24.

Oral thrombostatin FM19 inhibits prostate cancer.

Nieman MT, LaRusch G, Fang C, Zhou Y, Schmaier AH.

Thromb Haemost. 2010 Nov;104(5):1044-8. doi: 10.1160/TH09-08-0570. Epub 2010 Sep 30.

25.

AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis.

Xu F, Previti ML, Nieman MT, Davis J, Schmaier AH, Van Nostrand WE.

J Neurosci. 2009 Apr 29;29(17):5666-70. doi: 10.1523/JNEUROSCI.0095-09.2009.

26.
27.

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

Nieman MT, Burke F, Warnock M, Zhou Y, Sweigart J, Chen A, Ricketts D, Lucchesi BR, Chen Z, Di Cera E, Hilfinger J, Kim JS, Mosberg HI, Schmaier AH.

J Thromb Haemost. 2008 May;6(5):837-45. doi: 10.1111/j.1538-7836.2008.02937.x. Epub 2008 Feb 25.

28.

Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site.

Nieman MT, Schmaier AH.

Biochemistry. 2007 Jul 24;46(29):8603-10. Epub 2007 Jun 27.

29.

Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4.

Nieman MT, Pagan-Ramos E, Warnock M, Krijanovski Y, Hasan AA, Schmaier AH.

FEBS Lett. 2005 Jan 3;579(1):25-9.

30.

The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.

Nieman MT, Warnock M, Hasan AA, Mahdi F, Lucchesi BR, Brown NJ, Murphey LJ, Schmaier AH.

J Pharmacol Exp Ther. 2004 Nov;311(2):492-501. Epub 2004 Jun 21.

PMID:
15210836
31.

Characterization of cadherin-24, a novel alternatively spliced type II cadherin.

Katafiasz BJ, Nieman MT, Wheelock MJ, Johnson KR.

J Biol Chem. 2003 Jul 25;278(30):27513-9. Epub 2003 May 5.

32.

ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation.

Kolligs FT, Nieman MT, Winer I, Hu G, Van Mater D, Feng Y, Smith IM, Wu R, Zhai Y, Cho KR, Fearon ER.

Cancer Cell. 2002 Mar;1(2):145-55.

PMID:
12086873
33.

Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas.

Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, Kolligs FT, Nieman MT, Fearon ER, Cho KR.

Am J Pathol. 2002 Apr;160(4):1229-38.

34.

N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression.

Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ.

J Cell Biol. 1999 Nov 1;147(3):631-44.

35.

Mechanism of extracellular domain-deleted dominant negative cadherins.

Nieman MT, Kim JB, Johnson KR, Wheelock MJ.

J Cell Sci. 1999 May;112 ( Pt 10):1621-32.

36.

Cadherins promote skeletal muscle differentiation in three-dimensional cultures.

Redfield A, Nieman MT, Knudsen KA.

J Cell Biol. 1997 Sep 22;138(6):1323-31.

Supplemental Content

Loading ...
Support Center